Physicochemical Properties
| Molecular Formula | C₆H₉O₉P.₃/₂MG |
| Molecular Weight | 292.56 |
| Exact Mass | 277.967 |
| CAS # | 113170-55-1 |
| Related CAS # | L-Ascorbic acid 2-phosphate trisodium;66170-10-3;L-Ascorbic acid 2-phosphate;23313-12-4 |
| PubChem CID | 54679072 |
| Appearance | White to off-white solid powder |
| Hydrogen Bond Donor Count | 3 |
| Hydrogen Bond Acceptor Count | 9 |
| Rotatable Bond Count | 3 |
| Heavy Atom Count | 17 |
| Complexity | 357 |
| Defined Atom Stereocenter Count | 2 |
| SMILES | C([C@@H]([C@@H]1C(=C(C(=O)O1)OP(=O)([O-])[O-])O)O)O.[Mg+2] |
| InChi Key | ACFGRWJEQJVZTM-LEJBHHMKSA-L |
| InChi Code | InChI=1S/C6H9O9P.Mg/c7-1-2(8)4-3(9)5(6(10)14-4)15-16(11,12)13;/h2,4,7-9H,1H2,(H2,11,12,13);/q;+2/p-2/t2-,4+;/m0./s1 |
| Chemical Name | magnesium;[(2R)-2-[(1S)-1,2-dihydroxyethyl]-3-hydroxy-5-oxo-2H-furan-4-yl] phosphate |
| Synonyms | LAscorbic acid 2phosphate magnesium; L Ascorbic acid 2 phosphate magnesium |
| HS Tariff Code | 2934.99.9001 |
| Storage |
Powder-20°C 3 years 4°C 2 years In solvent -80°C 6 months -20°C 1 month Note: Please store this product in a sealed and protected environment, avoid exposure to moisture. |
| Shipping Condition | Room temperature (This product is stable at ambient temperature for a few days during ordinary shipping and time spent in Customs) |
Biological Activity
| ln Vitro | Cell growth was strongly enhanced by L-ascorbic acid 2-phosphate (0.1-1.5 mM; medium changes every 2–3 days for 2–3 weeks), but addition of L-ascorbic acid (Asc) only produced a mild growth stimulation. Cell growth is greatly enhanced by the combination of Asc-2P and bFGF; however, additional effects are not produced by the addition of EGF or insulin [1]. L-ascorbic acid 2-phosphate (50 µM–250 µM) is necessary for the efficient osteogenic differentiation of human adipose stem cells (hASCs), and AsA2-P concentrations greater than 50 µM cause an increase in runx2 expression and ALP activity. The combinations of 150 µM asA2-P and 10 nM dexamethasone (Dex) and 250 µM asA2-P and 5 nM Dex produced the maximum proliferation, ALP activity, and runx2 expression [3]. |
| Cell Assay |
Cell viability assay [1] Cell Types: human corneal endothelial cells (HCEC) Tested Concentrations: 0.1 mM; 0.3 mM; 1.5 mM Incubation Duration: 2 to 3 weeks, medium replacement every 2 to 3 days Experimental Results: Stimulated HCEC cell growth. |
| References |
[1]. Increased proliferation and replicative lifespan of isolated human corneal endothelial cells with L-ascorbic acid 2-phosphate.Invest Ophthalmol Vis Sci. 2011 Nov 7;52(12):8711-7. [2]. Epidermal growth factor inhibits transcription of type I collagen genes and production of type I collagen in cultured human skin fibroblasts in the presence and absence of L-ascorbic acid 2-phosphate, a long-acting vitamin C derivative.J Biol Chem. 1991 May 25;266(15):9997-10003. [3]. Effects of different serum conditions on osteogenic differentiation of human adipose stem cells in vitro.Stem Cell Res Ther. 2013 Feb 15;4(1):17. |
| Additional Infomation | Magnesium L-ascorbic acid-2-phosphate is an organic molecular entity. |
Solubility Data
| Solubility (In Vitro) | H2O : ~25 mg/mL (~85.45 mM) |
| Solubility (In Vivo) |
Note: Listed below are some common formulations that may be used to formulate products with low water solubility (e.g. < 1 mg/mL), you may test these formulations using a minute amount of products to avoid loss of samples. Injection Formulations (e.g. IP/IV/IM/SC) Injection Formulation 1: DMSO : Tween 80： Saline = 10 : 5 : 85 (i.e. 100 μL DMSO stock solution → 50 μL Tween 80 → 850 μL Saline) *Preparation of saline: Dissolve 0.9 g of sodium chloride in 100 mL ddH ₂ O to obtain a clear solution. Injection Formulation 2: DMSO : PEG300 ：Tween 80 : Saline = 10 : 40 : 5 : 45 (i.e. 100 μL DMSO → 400 μLPEG300 → 50 μL Tween 80 → 450 μL Saline) Injection Formulation 3: DMSO : Corn oil = 10 : 90 (i.e. 100 μL DMSO → 900 μL Corn oil) Example: Take the Injection Formulation 3 (DMSO : Corn oil = 10 : 90) as an example, if 1 mL of 2.5 mg/mL working solution is to be prepared, you can take 100 μL 25 mg/mL DMSO stock solution and add to 900 μL corn oil, mix well to obtain a clear or suspension solution (2.5 mg/mL, ready for use in animals). Injection Formulation 4: DMSO : 20% SBE-β-CD in saline = 10 : 90 [i.e. 100 μL DMSO → 900 μL (20% SBE-β-CD in saline)] *Preparation of 20% SBE-β-CD in Saline (4°C，1 week): Dissolve 2 g SBE-β-CD in 10 mL saline to obtain a clear solution. Injection Formulation 5: 2-Hydroxypropyl-β-cyclodextrin : Saline = 50 : 50 (i.e. 500 μL 2-Hydroxypropyl-β-cyclodextrin → 500 μL Saline) Injection Formulation 6: DMSO : PEG300 : castor oil : Saline = 5 : 10 : 20 : 65 (i.e. 50 μL DMSO → 100 μLPEG300 → 200 μL castor oil → 650 μL Saline) Injection Formulation 7: Ethanol : Cremophor : Saline = 10： 10 : 80 (i.e. 100 μL Ethanol → 100 μL Cremophor → 800 μL Saline) Injection Formulation 8: Dissolve in Cremophor/Ethanol (50 : 50), then diluted by Saline Injection Formulation 9: EtOH : Corn oil = 10 : 90 (i.e. 100 μL EtOH → 900 μL Corn oil) Injection Formulation 10: EtOH : PEG300：Tween 80 : Saline = 10 : 40 : 5 : 45 (i.e. 100 μL EtOH → 400 μLPEG300 → 50 μL Tween 80 → 450 μL Saline) Oral Formulations Oral Formulation 1: Suspend in 0.5% CMC Na (carboxymethylcellulose sodium) Oral Formulation 2: Suspend in 0.5% Carboxymethyl cellulose Example: Take the Oral Formulation 1 (Suspend in 0.5% CMC Na) as an example, if 100 mL of 2.5 mg/mL working solution is to be prepared, you can first prepare 0.5% CMC Na solution by measuring 0.5 g CMC Na and dissolve it in 100 mL ddH2O to obtain a clear solution; then add 250 mg of the product to 100 mL 0.5% CMC Na solution, to make the suspension solution (2.5 mg/mL, ready for use in animals). Oral Formulation 3: Dissolved in PEG400 Oral Formulation 4: Suspend in 0.2% Carboxymethyl cellulose Oral Formulation 5: Dissolve in 0.25% Tween 80 and 0.5% Carboxymethyl cellulose Oral Formulation 6: Mixing with food powders Note: Please be aware that the above formulations are for reference only. InvivoChem strongly recommends customers to read literature methods/protocols carefully before determining which formulation you should use for in vivo studies, as different compounds have different solubility properties and have to be formulated differently. (Please use freshly prepared in vivo formulations for optimal results.) |
| Preparing Stock Solutions | 1 mg | 5 mg | 10 mg | |
| 1 mM | 3.4181 mL | 17.0905 mL | 34.1810 mL | |
| 5 mM | 0.6836 mL | 3.4181 mL | 6.8362 mL | |
| 10 mM | 0.3418 mL | 1.7091 mL | 3.4181 mL |